These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 20395333)

  • 1. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.
    Michałowska I; Ćwikła JB; Pęczkowska M; Furmanek MI; Buscombe JR; Michalski W; Prejbisz A; Szperl M; Malinoc A; Moczulski D; Szutkowski Z; Kawecki A; Antoniewicz J; Pęczkowski P; Lewczuk A; Otto M; Cichocki A; Bednarek-Tupikowska G; Kabat M; Janaszek-Sitkowska H; Przybyłowska K; Janas J; Neumann HP; Januszewicz A
    Neuroendocrinology; 2015; 101(4):321-30. PubMed ID: 25791839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging.
    Abgral R; Leboulleux S; Déandreis D; Aupérin A; Lumbroso J; Dromain C; Duvillard P; Elias D; de Baere T; Guigay J; Ducreux M; Schlumberger M; Baudin E
    J Clin Endocrinol Metab; 2011 Mar; 96(3):665-71. PubMed ID: 21193541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
    Garin E; Le Jeune F; Devillers A; Cuggia M; de Lajarte-Thirouard AS; Bouriel C; Boucher E; Raoul JL
    J Nucl Med; 2009 Jun; 50(6):858-64. PubMed ID: 19443590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
    King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
    Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
    Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
    Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.
    Faggiano A; Grimaldi F; Pezzullo L; Chiofalo MG; Caracò C; Mozzillo N; Angeletti G; Santeusanio F; Lombardi G; Colao A; Avenia N; Ferolla P
    Endocr Relat Cancer; 2009 Mar; 16(1):225-31. PubMed ID: 19004986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
    Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
    J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas.
    Koopmans KP; Jager PL; Kema IP; Kerstens MN; Albers F; Dullaart RP
    J Nucl Med; 2008 Aug; 49(8):1232-7. PubMed ID: 18632829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
    Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J
    Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
    Shapiro B
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors.
    Kubota K; Okasaki M; Minamimoto R; Miyata Y; Morooka M; Nakajima K; Sato T
    Ann Nucl Med; 2014 Dec; 28(10):1004-10. PubMed ID: 25179521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up.
    Lepoutre-Lussey C; Caramella C; Bidault F; Déandreis D; Berdelou A; Al Ghuzlan A; Hartl D; Borget I; Gimenez-Roqueplo AP; Dumont F; Deschamps F; Nascimento C; Lumbroso J; Guillaud Bataille M; Schlumberger M; Baudin E; Leboulleux S
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):868-76. PubMed ID: 25676472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.